IQVIA Holdings - Morgan Stanley trims rating and target
17.06.2026 - 19:59:42 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:55 UTC. Details in the imprint.
IQVIA Holdings (US46266C1053) faces a fresh dose of analyst caution after Morgan Stanley downgraded the stock from Overweight to Equal-weight and cut its price target to $200 from $225, according to a Morgan Stanley update summarized by MarketScreener on 06/17/2026.
All news and key data on IQVIA Holdings
Background reports, filings and further market coverage help frame today’s analyst move around IQVIA Holdings.
Morgan Stanley turns more cautious
The Morgan Stanley move shifts IQVIA from a previous Overweight stance to Equal-weight, with the target reduced by $25 to $200 per share. That new target now sits modestly above the stock’s recent trading range around the high-$170s.
MarketScreener cites the downgrade as part of a broader analyst update list, where IQVIA’s cut contrasts with more constructive moves on other healthcare names. Earlier commentary from Morgan Stanley had highlighted growth prospects in data and analytics, but the new rating now signals a more neutral stance.
How the broader consensus looks now
Despite the downgrade, the analyst community remains broadly constructive on IQVIA. MarketBeat data shows an average recommendation of "Buy" and a consensus price target around $224 to $227 per share. That implies double-digit upside from current levels.
TradingView compiles 12-month price targets that have edged down slightly, with the average slipping from about $224.67 to roughly $223.28 per share, based on estimates from 18 analysts. The range of forecasts runs from roughly $195 to $287, underlining a still-wide spread of views on the stock’s fair value.
The business behind the numbers
IQVIA describes itself as a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company’s data assets and analytics platforms help pharmaceutical and biotech customers design clinical trials, track real-world outcomes and optimize commercial strategies.
According to the company, IQVIA serves customers in more than 100 countries, combining extensive healthcare data with AI-enabled tools. This positioning places the group at the intersection of drug development, regulatory evidence generation and commercial execution, which has been a structural growth area for several years.
Recent share performance and valuation markers
On 06/17/2026, MarketScreener quoted IQVIA shares around $179.17, with a 52-week range between roughly $153 and $247. MarketBeat also notes a recent open price close to that level and highlights that the stock has an average analyst rating of Buy.
Valuation-wise, MarketBeat lists a market cap near $33 billion and points to leverage and profitability metrics that investors track closely, including a debt-to-equity ratio above 2 and an operating margin in the mid-teens. Against the consensus target, the current price implies a discount in the mid-20% range, depending on the reference estimate.
What the company sells
IQVIA’s revenue mix is anchored in its Technology & Analytics Solutions and Research & Development Solutions businesses, which include its IQVIA CORE data platform and global clinical research organization services. These offerings support customers from early clinical trial design through post-launch real-world evidence studies.
Where the stock trades today
The shares of IQVIA Holdings (US46266C1053) trade on the New York Stock Exchange at $181.46 as of 06/17/2026, 16:00 ET.
IQVIA Holdings at a glance
- Company: IQVIA Holdings Inc.
- ISIN: US46266C1053
- WKN: A2JTXJ
- Ticker: IQV
- Venue: NYSE
- Price (as of 06/17/2026, 16:00 ET): 181.46 USD
- Market cap: 33,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
